Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects

Medical Hypotheses

Volumn 69, Issue 6, 2007, Pages 1219-1221

  Tsai, Shih Jen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DJ 1 PROTEIN; DOPAMINE; GLATIRAMER; INTERLEUKIN 1; INTERLEUKIN 6; PARKIN; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; ANXIETY; APPLICATION SITE PRURITUS; ARTICLE; COGNITION; DOPAMINE METABOLISM; DRUG EFFICACY; DYSPNEA; FLUSHING; HEART PALPITATION; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOKINES; DOPAMINE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MICE; MICE, TRANSGENIC; MODELS, THEORETICAL; NEURONS; PARKINSON DISEASE; PEPTIDES;

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 35448929105     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.04.014     Document Type: Article

References (21)

1. Bonuccelli U., and Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology 67 7 Suppl 2 (2006) S30-S38
2. Wolinsky J.S. Glatiramer acetate for the treatment of multiple sclerosis. Expert Opin Pharmacother 5 (2004) 875-891
3. Fiore A.P., and Fragoso Y.D. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months. Arq Neuropsiquiatr 63 3B (2005) 738-740
4. Farina C., Weber M.S., Meinl E., Wekerle H., and Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 4 (2005) 567-575
5. Perumal J., Filippi M., Ford C., Johnson K., Lisak R., Metz L., et al. Glatiramer acetate therapy for multiple sclerosis: a review. Expert Opin Drug Metab Toxicol 2 (2006) 1019-1029
6. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 103 (2006) 11784-11789
7. Frenkel D., Maron R., Burt D.S., and Weiner H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 115 (2005) 2423-2433
8. Tsai S.J. Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Med Hypotheses 69 (2007) 145-148
9. Murer M.G., Yan Q., and Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63 (2001) 71-124
10. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
11. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 10 (1999) 557-561
12. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 270 (1999) 45-48
13. Tsukahara T., Takeda M., Shimohama S., Ohara O., and Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37 (1995) 733-739
14. Singh S., Ahmad R., Mathur D., Sagar R.K., and Krishana B. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease. Indian J Exp Biol 44 (2006) 699-704
15. Ziemssen T., Kumpfel T., Klinkert W.E., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125 (2002) 2381-2391
16. Aharoni R., Kayhan B., Eilam R., Sela M., and Arnon R. Glatiramer acetate-specific T cells in the brain express T-helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100 (2003) 14157-14162
17. Azoulay D., Vachapova V., Shihman B., Miler A., and Karni A. Lower brain-derived neurotrophic factor in serum of relapsings-remitting MS: reversal by glatiramer acetate. J Neuroimmunol 167 (2005) 215-218
18. Wersinger C., and Sidhu A. Inflammation and Parkinson's disease. Curr Drug Targets Inflamm Allergy 1 (2002) 221-242
19. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., and Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202 (1995) 17-20
20. Araujo D.M., and Lapchak P.A. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 61 (1994) 745-754
21. Dawson T.M., and Dawson V.L. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111 (2003) 145-151